Media Articles Related to Buprenex (Buprenorphine)
Suboxone Maker Pulls Pills in Favor of Film
Source: MedPage Today Product Alert [2012.09.25]
The buprenorphine-naloxone combination product (Suboxone) in sublingual tablet form will soon be pulled from the U.S. market because its child-resistant packaging isn't effective enough.
Published Studies Related to Buprenex (Buprenorphine)
Analgesia after feline ovariohysterectomy under midazolam-medetomidine-ketamine
anaesthesia with buprenorphine or butorphanol, and carprofen or meloxicam: a
prospective, randomised clinical trial. 
One hundred female cats undergoing routine ovariohysterectomy under
midazolam-medetomidine-ketamine anaesthesia were included in a blinded,
randomised, prospective clinical study to compare postoperative analgesia
produced by four analgesic drug combinations given preoperatively (n = 25 per
Effect of buprenorphine dose on treatment outcome. 
The goal of this meta-analysis is to provide evidence based information about
proper dosing for buprenorphine maintenance treatment to improve treatment
outcome. To be selected for the review and inclusion in the meta-analysis,
articles had to be randomized, controlled, or double-blind clinical trials, with
buprenorphine as the study drug; the length of buprenorphine maintenance
treatment had to be 3 weeks or longer; doses of buprenorphine had to be clearly
stated; outcome measures had to include retention rates in buprenorphine
treatment; outcome measures had to include illicit opioid use based on analytical
determination of drugs of abuse in urine samples as outcome variables; and
outcome measures had to include illicit cocaine use based on analytical
determination of drugs of abuse in urine samples as outcome variables.
Sublingual buprenorphine in acute pain management: a double-blind randomized
clinical trial. 
bone fracture... CONCLUSION: For adults with acute fractures, buprenorphine 0.4 mg sublingually is
Buprenorphine 5, 10 and 20 mug/h Transdermal Patch: A Review of its Use in the Management of Chronic Non-Malignant Pain. [2011.12.24]
This article reviews the pharmacology, therapeutic efficacy and tolerability profile of the 7-day lower-dose (5, 10 and 20 mug/h) buprenorphine transdermal patch (BuTrans(R), Norspan(R)) in the management of chronic non-malignant pain, with a focus on European labelling for the drug... It also has favourable pharmacodynamic and pharmacokinetic properties, which have beneficial clinical implications, most notably the convenience of once-weekly administration and no need for dosage adjustments in the elderly or those with compromised renal function, making it an opioid of choice in these patients, and a useful therapeutic option overall in the management of chronic non-malignant pain.
Results of a pilot randomized controlled trial of buprenorphine for opioid dependent women in the criminal justice system. [2011.12.15]
AIMS: Recent studies have demonstrated the efficacy of both methadone and buprenorphine when used with opioid dependent men transitioning from prison to the community, but no studies have been conducted with women in the criminal justice (CJ) system. The aim of this study was to determine the efficacy of buprenorphine for relapse prevention among opioid dependent women in the CJ system transitioning back to the community... CONCLUSIONS: Women in the CJ system who received buprenorphine prior to release from a treatment facility had fewer opiate positive UDS through the 12 weeks of treatment compared to women receiving placebo. Initiating buprenorphine in a controlled environment prior to release appears to be a viable strategy to reduce opiate use when transitioning back to the community. Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.
Clinical Trials Related to Buprenex (Buprenorphine)
Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphin/Naloxone) in Opioid Dependent Patients on Subutex (Study P05094)(COMPLETED) [Completed]
This study is designed to determine if opioid dependent subjects who are already receiving
Subutex prefer the Suboxone tablet over the Subutex tablet after switching from Subutex to
Suboxone. Subjects who are selected to participate in this study will continue their
prescribed dose of Subutex (buprenorphin 2 to 16 mg daily) for the first two days of the
study (Day 1 and Day 2) then switch to and receive an equivalent dose of Suboxone
(buprenorphine 2 to 16 mg daily) for the last 3 days of the study (Day 3, Day 4 and Day 5).
The Day 5 Visit will be the subject's last study visit. Upon completing the study, subjects
will continue their pre-study prescribed dosage of Subutex.
Buprenorphine for the Treatment of Neonatal Abstinence Syndrome [Recruiting]
Neonatal abstinence syndrome is a disease that affects children who were exposed to opioid
drugs prior to birth. Commonly used treatments at present include morphine or tincture of
opium. Buprenorphine is a drug used in adults to treat narcotic dependence, but has not
been used for Neonatal Abstinence Syndrome. This trial is designed to see if the use of
sublingual (under the tongue) buprenorphine is able to be used safely and easily in newborns
with the neonatal abstinence syndrome. Secondary goals will be to see if treatment with
buprenorphine is associated shorter stays in the hospital and fewer days of treatment than
the use of standard therapy. Another secondary goal will be to understand buprenorphine
concentration in the blood of babies treated with the drug (this is called
Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME") [Recruiting]
Patients who admit to using buprenorphine by the intravenous route will be randomized to
either Subutex or Suboxone and be followed up for 3 months to determine if there is less
injection with Suboxone than with Subutex based primarily on patient diaries.
Patients randomized to Suboxone may continue to receive the product for a further 9 months
at their request and will be monitored at 3 month intervals.
Patients will receive a payment for the inconvenience of keeping a daily diary and to cover
their travel expenses.
Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir [Completed]
The main purpose of this study is to examine the effect of tipranavir combined with
ritonavir, medications for the treatment of HIV-infection, on buprenorphine/naloxone (BUP) in
people who have been receiving the same dose of buprenorphine/naloxone for at least 3 weeks
before study entry.
A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123 AM3) [Recruiting]
In this study, participants on methadone or buprenorphine/naloxone maintenance therapy will
be given boceprevir. Blood samples will be taken at specified intervals to find out whether
boceprevir affects the pharmacokinetics of methadone or buprenorphine/naloxone.